The Impact of the Approval of Radium-223

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.

Shore expects a remarkable new thought process regarding the treatment of bone metastases in relation to the drug's approval. In addition to the amelioration of pain and delay to the onset of radiation requirement for painful bone metastases, radium-223 also demonstrated delays to skeletal events (surgical intervention, cord compression).

Clinical Pearls

Radium-223 is unique, Shore says, in that it prolonged survival: The final analysis showed a 3.6-month improvement to overall survival.

  • Shore anticipates a new thought process for the treatment of bone metastases from prostate cancer
  • Radium-223 showed amelioration of pain, delay to the onset of radiation requirement for bone mets, and delays in skeletal events
  • Radium-223 demonstrated a 3.6-month improvement to overall survival

<<<

View all coverage from the 2013 ASCO Meeting